3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
2
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Rhabdomyosarcoma
1
Recurrence
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Diseases
1
Neuroblastoma
1
Neoplasm Metastasis
1
Medulloblastoma
1
Liver Neoplasms
1
Hepatoblastoma
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Fibrosis
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma
1
Breast Neoplasms
1
Basal Cell Nevus Syndrome
1
Astrocytoma
1
Interventions
trametinib
3
pertuzumab
3
dabrafenib
3
Specimen Handling
3
Nivolumab
3
Bevacizumab
3
venetoclax
2
palbociclib
2
copanlisib
2
cobimetinib
2
Vemurafenib
2
Trastuzumab
2
Sunitinib
2
Sorafenib
2
Oxaliplatin
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Ipilimumab
2
Immunoglobulin G
2
HhAntag691
2
Fluorouracil
2
Disulfides
2
Dasatinib
2
CTLA-4 Antigen
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
2C4 antibody
2
vactosertib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
sonidegib
×
Gastrointestinal
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts